Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. The Company is headquartered in Victoria, BC and focuses its development efforts globally.
#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical and Medicine Industry (3741)